KR20180014221A - 뇌내 출혈을 치료하기 위한 조성물 및 방법 - Google Patents

뇌내 출혈을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20180014221A
KR20180014221A KR1020187002632A KR20187002632A KR20180014221A KR 20180014221 A KR20180014221 A KR 20180014221A KR 1020187002632 A KR1020187002632 A KR 1020187002632A KR 20187002632 A KR20187002632 A KR 20187002632A KR 20180014221 A KR20180014221 A KR 20180014221A
Authority
KR
South Korea
Prior art keywords
less
ich
fxa
hours
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187002632A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 아킨
조아힘 프루비스
마커스 이. 카
서니타 헷
리마 자수자
데브라 디. 피트맨
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20180014221A publication Critical patent/KR20180014221A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187002632A 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법 Ceased KR20180014221A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167019778A Division KR20160093731A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217001254A Division KR20210008177A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20180014221A true KR20180014221A (ko) 2018-02-07

Family

ID=52630418

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187002632A Ceased KR20180014221A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020167019778A Ceased KR20160093731A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020217001254A Ceased KR20210008177A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167019778A Ceased KR20160093731A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020217001254A Ceased KR20210008177A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Country Status (18)

Country Link
US (2) US20160375109A1 (enExample)
EP (1) EP3096779B1 (enExample)
JP (1) JP6624787B2 (enExample)
KR (3) KR20180014221A (enExample)
CN (2) CN112156176A (enExample)
AU (1) AU2015208819B2 (enExample)
BR (1) BR112016014617A2 (enExample)
CA (1) CA2937418A1 (enExample)
DK (1) DK3096779T3 (enExample)
ES (1) ES2772802T3 (enExample)
HU (1) HUE047588T4 (enExample)
IL (1) IL246637A0 (enExample)
MX (1) MX375355B (enExample)
PL (1) PL3096779T3 (enExample)
PT (1) PT3096779T (enExample)
RU (1) RU2016126423A (enExample)
SI (1) SI3096779T1 (enExample)
WO (1) WO2015110939A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123118A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) * 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa

Also Published As

Publication number Publication date
EP3096779B1 (en) 2019-12-18
US20190231856A1 (en) 2019-08-01
RU2016126423A (ru) 2018-03-01
AU2015208819B2 (en) 2020-01-23
ES2772802T3 (es) 2020-07-08
MX2016009665A (es) 2016-11-14
CA2937418A1 (en) 2015-07-30
JP2015147764A (ja) 2015-08-20
HUE047588T4 (hu) 2020-06-29
EP3096779A1 (en) 2016-11-30
US20160375109A1 (en) 2016-12-29
IL246637A0 (en) 2016-08-31
DK3096779T3 (da) 2020-02-24
AU2015208819A1 (en) 2016-06-30
WO2015110939A1 (en) 2015-07-30
KR20160093731A (ko) 2016-08-08
MX375355B (es) 2025-03-04
CN112156176A (zh) 2021-01-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
BR112016014617A2 (pt) 2017-09-19
SI3096779T1 (sl) 2020-03-31
RU2016126423A3 (enExample) 2018-03-01
JP6624787B2 (ja) 2019-12-25
HUE047588T2 (hu) 2020-04-28
CN105934250A (zh) 2016-09-07
PT3096779T (pt) 2020-02-21

Similar Documents

Publication Publication Date Title
EP3307296B1 (en) Timp2 for use in treating aging-associated conditions
TW200817033A (en) Method of treating stroke with thrombolytic agent
US9732334B2 (en) Mutated tissue plasminogen activators and uses thereof
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
CN113795274A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
KR20230005298A (ko) 척수성 근위축증의 치료 방법 및 약물
JP6629744B2 (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
EP3420087B1 (en) Peptide-based methods for treating neurological injury
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
HK1228257A1 (en) Compositions and methods for treating intracerebral hemorrhage
JP7237085B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
KR102597725B1 (ko) 혈우병의 예방적 치료를 위해 인자 ix 및 사람 알부민을 포함하는 융합 단백질에 대한 21-일 투여 용법 및 이의 방법
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
HK1240124A1 (en) Method for preventing or treating diabetic nerve injury and related diseases

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180126

Application number text: 1020167019778

Filing date: 20160720

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200313

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201015

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200313

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210114

Application number text: 1020167019778

Filing date: 20160720